The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing

Behavioural Brain Research

Volumn 183, Issue 2, 2007, Pages 161-168

  Cannon, Jason R ^a,b,c   Hua, Ya ^a   Richardson, Rudy J ^a,b   Xi, Guohua ^a   Keep, Richard F ^a,b   Schallert, Timothy ^a,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Brain injury; PAR 1; Parkinson's disease; Protease activated receptor 1; Sensorimotor

Indexed keywords

CATECHOLAMINE; NEUROTOXIN; OXIDOPAMINE; PROTEINASE ACTIVATED RECEPTOR 1; SODIUM CHLORIDE; THROMBIN; THROMBIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; CONDITIONING; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG EFFECT; MALE; MEDIAL FOREBRAIN BUNDLE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEPLETION; RAT; STROKE;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; CATECHOLAMINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HEMOSTATICS; MALE; MEDIAL FOREBRAIN BUNDLE; OLIGOPEPTIDES; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; THROMBIN;

EID: 34548295863     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2007.06.004     Document Type: Article

References (46)

1. Akiyama H., Ikeda K., Kondo H., and McGeer P.L. Thrombin accumulation in brains of patients with Alzheimer's disease. Neurosci Lett 146 (1992) 152-154
2. Arand A.G., and Sawaya R. Intraoperative chemical hemostasis in neurosurgery. Neurosurgery 18 (1986) 223-233
3. Cannon J.R., Keep R.F., Hua Y., Richardson R.J., Schallert T., and Xi G. Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model. Neurosci Lett 373 (2005) 189-194
4. Cannon J.R., Keep R.F., Schallert T., Hua Y., Richardson R.J., and Xi G. Protease-activated receptor-1 mediates protection elicited by thrombin preconditioning in a rat 6-hydroxydopamine model of Parkinson's disease. Brain Res 1116 (2006) 177-186
5. Carreno-Muller E., Herrera A.J., de Pablos R.M., Tomas-Camardiel M., Venero J.L., Cano J., et al. Thrombin induces in vivo degeneration of nigral dopaminergic neurones along with the activation of microglia. J Neurochem 84 (2003) 1201-1214
6. Carvey P.M., Zhao C.H., Hendey B., Lum H., Trachtenberg J., Desai B.S., et al. 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. Eur J Neurosci 22 (2005) 1158-1168
7. Cavanaugh K.P., Gurwitz D., Cunningham D.D., and Bradshaw R.A. Reciprocal modulation of astrocyte stellation by thrombin and protease nexin-1. J Neurochem 54 (1990) 1735-1743
8. Choi S.H., Joe E.H., Kim S.U., and Jin B.K. Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo. J Neurosci 23 (2003) 5877-5886
9. Choi S.H., Lee Y.D., Ryu J.K., Kim J., Joe E.H., and Jin B.K. Thrombin induces nigral dopaminergic neurodegeneration in vivo by altering expression of death-related proteins. Neurobiol Dis 14 (2003) 181-193
10. Choi S.H., Lee da Y., Chung E.S., Hong Y.B., Kim S.U., and Jin B.K. Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. J Neurochem 95 (2005) 1755-1765
11. Colon G.P., Lee K.R., Keep R.F., Chenevert T.L., Betz A.L., and Hoff J.T. Thrombin-soaked gelatin sponge and brain edema in rats. J Neurosurg 85 (1996) 335-339
12. Coughlin S.R. Protease-activated receptors start a family. Proc Natl Acad Sci USA 91 (1994) 9200-9202
13. Dery O., Corvera C.U., Steinhoff M., and Bunnett N.W. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol 274 (1998) C1429-C1452
14. Ehrenreich H., Costa T., Clouse K.A., Pluta R.M., Ogino Y., Coligan J.E., et al. Thrombin is a regulator of astrocytic endothelin-1. Brain Res 600 (1993) 201-207
15. Gidday J.M. Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci 7 (2006) 437-448
16. Hamill CE, Caudle WM, Richardson JR, Miller GW, Traynelis SF. Role for protease-activated receptor 1 (PAR1) in MPTP-induced dopaminergic neurotoxicity. Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience; 2004; Program No. 562.6: Online.
17. Hua Y., Wu J., Keep R.F., Hoff J.T., and Xi G. Thrombin exacerbates brain edema in focal cerebral ischemia. Acta Neurochir 86 Suppl. (2003) 163-166
18. Hua Y., Wu J., Pecina S., Yang S., Schallert T., Keep R.F., et al. Ischemic preconditioning procedure induces behavioral deficits in the absence of brain injury?. Neurol Res 27 (2005) 261-267
19. Inoue H., Udaka F., Takahashi M., Nishinaka K., and Kameyama M. Secondary parkinsonism following midbrain hemorrhage. Rinsho Shinkeigaku 37 (1997) 266-269
20. Ishida Y., Nagai A., Kobayashi S., and Kim S.U. Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase. J Neuropathol Exp Neurol 65 (2006) 66-77
21. Jiang Y., Wu J., Hua Y., Keep R.F., Xiang J., Hoff J.T., et al. Thrombin-receptor activation and thrombin-induced brain tolerance. J Cerebr Blood Flow Metab 22 (2002) 404-410
22. Kortekaas R., Leenders K.L., van Oostrom J.C., Vaalburg W., Bart J., Willemsen A.T., et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57 (2005) 176-179
23. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
24. Langston J.W., Forno L.S., Rebert C.S., and Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 292 (1984) 390-394
25. Lee D.Y., Oh Y.J., and Jin B.K. Thrombin-activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: dual roles of mitogen-activated protein kinase signaling pathways. Glia 51 (2005) 98-110
26. Lee K.R., Colon G.P., Betz A.L., Keep R.F., Kim S., and Hoff J.T. Edema from intracerebral hemorrhage: the role of thrombin. J Neurosurg 84 (1996) 91-96
27. Lee K.R., Kawai N., Kim S., Sagher O., and Hoff J.T. Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model. J Neurosurg 86 (1997) 272-278
28. Ling M.J., Aggarwal A., and Morris J.G. Dopa-responsive parkinsonism secondary to right temporal lobe haemorrahage. Mov Disord 17 (2002) 402-404
29. Masada T., Xi G., Hua Y., and Keep R.F. The effects of thrombin preconditioning on focal cerebral ischemia in rats. Brain Res 867 (2000) 173-179
30. Matsuda W., Sugimoto K., Sato N., Watanabe T., Yanaka K., Matsumura A., et al. A case of primary brain-stem injury recovered from persistent vegetative state after l-dopa administration. No To Shinkei 51 (1999) 1071-1074
31. Mhatre M., Nguyen A., Kashani S., Pham T., Adesina A., and Grammas P. Thrombin, a mediator of neurotoxicity and memory impairment. Neurobiol Aging 25 (2004) 783-793
32. Neveu I., Jehan F., Jandrot-Perrus M., Wion D., and Brachet P. Enhancement of the synthesis and secretion of nerve growth factor in primary cultures of glial cells by proteases: a possible involvement of thrombin. J Neurochem 60 (1993) 858-867
33. Schallert T. Aging-dependent emergence of sensorimotor dysfunction in rats recovered from dopamine depletion sustained early in life. In: Joseph JA, editor. Central Determinants of Age-related Declines in Motor Function, vol. 515. New York. Ann NY Acad Sci 1988;108-120.
34. Schallert T. Sensorimotor impairment and recovery of function in brain-damaged rats: reappearance of symptoms during old age. Behav Neurosci 97 (1983) 159-164
35. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., and Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39 (2000) 777-787
36. Schallert T., and Wilcox R.E. Neurotransmitter-selective brain lesions. In: Boulton A.A., and Baker G.B. (Eds). Neuromethods vol. 1 (1985), Humana Press, Clifton 343-387
37. Striggow F., Riek M., Breder J., Henrich-Noack P., Reymann K.G., and Reiser G. The protease thrombin is an endogenous mediator of hippocampal neuroprotection against ischemia at low concentrations but causes degeneration at high concentrations. Proc Natl Acad Sci USA 97 (2000) 2264-2269
38. Teismann P., and Schulz J.B. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res 318 (2004) 149-161
39. Tillerson J.L., Cohen A.D., Philhower J., Miller G.W., Zigmond M.J., and Schallert T. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J Neurosci 21 (2001) 4427-4435
40. Uryu K., Giasson B.I., Longhi L., Martinez D., Murray I., Conte V., et al. Age-dependent synuclein pathology following traumatic brain injury in mice. Exp Neurol 184 (2003) 214-224
41. Vaughan P.J., Pike C.J., Cotman C.W., and Cunningham D.D. Thrombin receptor activation protects neurons and astrocytes from cell death produced by environmental insults. J Neurosci 15 (1995) 5389-5401
42. Wang H., and Reiser G. Thrombin signaling in the brain: the role of protease-activated receptors. Biol Chem 384 (2003) 193-202
43. Wang H., Ubl J.J., and Reiser G. Four subtypes of protease-activated receptors, co-expressed in rat astrocytes, evoke different physiological signaling. Glia 37 (2002) 53-63
44. Woodlee M.T., and Schallert T. The interplay between behavior and neurodegeneration in rat models of Parkinson's disease and stroke. Restor Neurol Neurosci 22 (2004) 153-161
45. Xi G., Keep R.F., Hua Y., Xiang J., and Hoff J.T. Attenuation of thrombin-induced brain edema by cerebral thrombin preconditioning. Stroke 30 (1999) 1247-1255
46. Xi G., Reiser G., and Keep R.F. The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective?. J Neurochem 84 (2003) 3-9